# CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy

> **NCT03068416** · PHASE2 · COMPLETED · sponsor: **Uppsala University** · enrollment: 24 (actual)

## Conditions studied

- B-cell Leukemia
- B-Cell Lymphoma

## Interventions

- **BIOLOGICAL:** CAR T cells

## Key facts

- **NCT ID:** NCT03068416
- **Lead sponsor:** Uppsala University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-18
- **Primary completion:** 2021-08-19
- **Final completion:** 2021-08-19
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-10-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03068416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03068416, "CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03068416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*